$10.3 M

CLRB Mkt cap, 16-Aug-2018
Cellectar Biosciences Net income (Q2, 2018)-6.4 M
Cellectar Biosciences EBIT (Q2, 2018)-6.4 M
Cellectar Biosciences Cash, 30-Jun-20184.2 M

Cellectar Biosciences Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

6.9 m6 m5.2 m4.8 m9.5 m

General and administrative expense

4.4 m3.7 m3.4 m4.7 m4.1 m

Operating expense total

11.3 m9.7 m8.6 m9.4 m13.6 m

EBIT

(12.4 m)(9.9 m)(8.8 m)(9.4 m)(13.6 m)

Interest expense

9.3 k446.3 k841 7.9 k16.6 k

Interest income

7.9 k16.6 k

Net Income

(10.8 m)(8.1 m)(5.5 m)(6.2 m)(13.6 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

R&D expense

1.4 m1.5 m1.6 m1.4 m1.2 m1 m965.2 k1.3 m1.9 m2.1 m3.8 m

General and administrative expense

959.9 k802.8 k943.4 k817.7 k834.9 k961.3 k1.4 m1.2 m955.4 k1.3 m2.6 m

Operating expense total

2.3 m2.3 m2.6 m2.2 m2 m2 m2.3 m2.5 m2.8 m3.5 m6.4 m

EBIT

(2.5 m)(2.3 m)(2.6 m)(2.3 m)(2.1 m)(2 m)(2.3 m)(2.5 m)(2.8 m)(3.5 m)(6.4 m)

Interest expense

114 k253.1 k2 k449 617 549 1.6 k3.1 k

Interest income

449 617 549 1.6 k3.1 k4.7 k8.9 k

Net Income

(2.1 m)(505.7 k)(2.3 m)(2.3 m)(1.9 m)824.6 k(2.1 m)(2.3 m)(2.9 m)(3.5 m)(6.4 m)

Cellectar Biosciences Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2.4 m9.4 m3.9 m11.4 m10 m

Inventories

294.7 k220.6 k267.8 k693.6 k

Current Assets

2.8 m9.7 m4.2 m12.2 m10.9 m

PP&E

244.7 k

Goodwill

1.7 m1.7 m1.7 m1.7 m1.7 m

Total Assets

6.8 m13.4 m7.6 m15.3 m12.9 m

Accounts Payable

1.4 m1.9 m

Short-term debt

450 k119.9 k243.6 k86.6 k

Current Liabilities

4.5 m2.2 m5.7 m1.6 m2.1 m

Long-term debt

450 k

Non-Current Liabilities

593.2 k489 k243.5 k151.8 k2.2 k

Total Debt

900 k86.6 k

Total Liabilities

5.1 m2.7 m5.9 m1.8 m2.1 m

Additional Paid-in Capital

52.8 m69.9 m66.3 m83.5 m94.1 m

Retained Earnings

(59.2 m)(64.6 m)(70.8 m)(84.3 m)

Total Equity

1.6 m13.5 m10.8 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0.1 x0 x

Financial Leverage

4.6 x1.1 x1.2 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Cash

1.6 m11.6 m7 m4.8 m2.5 m1.9 m7.9 m5.6 m11.2 m6.8 m4.2 m

Current Assets

2 m11.9 m7.3 m5 m3 m2.2 m8.1 m6.1 m12.2 m7.6 m5 m

PP&E

228.8 k212 k

Goodwill

1.7 m1.7 m1.7 m1.7 m1.7 m1.7 m1.7 m1.7 m1.7 m1.7 m1.7 m

Total Assets

5.9 m15.7 m10.9 m8.6 m6.5 m5.6 m11.4 m9.3 m15.3 m9.6 m7 m

Accounts Payable

1.2 m1.1 m824.2 k712.2 k579.8 k608.7 k816.8 k1.1 m1.2 m1.9 m2.1 m

Short-term debt

41.3 k103.3 k180.4 k240.8 k242.4 k244.8 k208.9 k147.9 k

Current Liabilities

4.1 m2.1 m5.9 m5.8 m5.5 m2.8 m1.4 m1.4 m1.4 m2.1 m2.3 m

Non-Current Liabilities

4.4 m505.1 k427.8 k367 k305.8 k180.8 k154.9 k153.8 k149.9 k1.4 k568

Total Liabilities

2.1 m2.3 m

Additional Paid-in Capital

53.5 m69.7 m66 m66.1 m66.2 m66.4 m75.7 m75.9 m87.4 m94.6 m95.5 m

Retained Earnings

(65.9 m)(73.7 m)(87.8 m)(90.7 m)

Total Equity

(2.5 m)13.1 m2.4 m680.2 k2.6 m9.8 m7.7 m13.7 m7.5 m4.7 m

Financial Leverage

-2.3 x1.2 x3.6 x9.5 x2.2 x1.2 x1.2 x1.1 x1.3 x1.5 x

Cellectar Biosciences Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(10.8 m)(8.1 m)(5.5 m)(6.2 m)(13.6 m)

Depreciation and Amortization

424.8 k367.2 k362.5 k356.7 k1.5 m

Inventories

48.1 k74.1 k(8.6 k)(464.4 k)

Accounts Payable

451.3 k

Short-term Borrowings

(617.5 k)

Cash From Financing Activities

5 m15.9 m2.7 m15.9 m9.9 m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(2.1 m)(505.7 k)(2.3 m)(2.3 m)(1.9 m)824.6 k(2.1 m)(2.3 m)(2.9 m)(3.5 m)(6.4 m)

Depreciation and Amortization

17.3 k34.2 k

Accounts Payable

16 k225.9 k

Cellectar Biosciences Ratios

USDY, 2018

Financial Leverage

1.5 x
Report incorrect company information